Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.61 |
| ▸ | NAMPT | P43490 | 12/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.59 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.59 |
| ▸ | TAS1R2 | Q8TE23 | 6/20 | 0.59 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5521225 | 0.87 | RAB9A (0.67) | NOTUMTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL15029231 | 0.82 | TRAP1 (0.49) | NOTUMNAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5662918 | 0.80 | NOTUM (0.58) | NOTUMTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL12942525 | 0.80 | NAMPT (0.52) | NAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL14959570 | 0.79 | NAMPT (0.55) | NAMPT | |
| SCHEMBL31414516 | 0.79 | ABHD6 (0.52) | NOTUMNAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL25871025 | 0.79 | NAMPT (0.62) | NOTUMNAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL26257474 | 0.79 | NAMPT (0.67) | NOTUMNAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL17169484 | 0.79 | NOTUM (0.55) | NOTUMNAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29824272 | 0.78 | DPP9 (0.56) | NAMPTTAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115087486-A | Substituted bicyclic and tricyclic ureas and amides, analogs thereof, and methods of use thereof | 爱彼特生物制药公司 | 2022-09-20 | — | — | CN | disclosed |
| US-10975101-B2 | Ultra-potent vinca alkaloids: added molecular complexity further disrupts the tublin dimer-dimer interface | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200317696-A1 | ULTRA-POTENT VINA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBLIN DIMER-DIMER INTERFACE | NATIONAL INSTITUTES OF HEALTH | 2020-10-08 | — | — | US | disclosed |
| US-9611271-B2 | C20′ urea derivatives of vinca alkaloids | SCRIPPS RESEARCH INSTITUTE (US) | 2017-04-04 | — | — | US | disclosed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160031880-A1 | Nampt and Rock Inhibitors | ABBVIE INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20150291610-A1 | C20' Urea Derivatives of Vinca Alkaloids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | NOTUM 2598/4885NAMPT 1/4885TAS1R3 4597/4885 |
| US-10975101-B2 | Ultra-potent vinca alkaloids: added molecular complexity further disrupts the tublin dimer-dimer interface | TUBA1C, TUBB2A, TUBA1A | NOTUM 2451/4885NAMPT 3573/4885TAS1R3 4283/4885 |
| US-20200317696-A1 | ULTRA-POTENT VINA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBLIN DIMER-DIMER INTERFACE | TUBA1A, TUBA1C, TUBB2A | NOTUM 2548/4885NAMPT 3614/4885TAS1R3 4284/4885 |
| US-20160031880-A1 | Nampt and Rock Inhibitors | NAMPT, NNMT, NME2 | NOTUM 2598/4885NAMPT 1/4885TAS1R3 4597/4885 |
| US-20150291610-A1 | C20' Urea Derivatives of Vinca Alkaloids | UTP18, SNRPA1, SNRPA | NOTUM 2370/4885NAMPT 925/4885TAS1R3 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.